A novel 2-pyrone derivative, BHP, impedes oncogenic KRAS-driven malignant progression in breast cancer

Rae Kwon Kim, Yongjoon Suh, Eun Jung Lim, Ki Chun Yoo, Ga Haeng Lee, Yan Hong Cui, Arang Son, Eunji Hwang, Nizam Uddin, Joo Mi Yi, Seok Gu Kang, Su Jae Lee

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Elevated KRAS expression has been frequently associated with cancer progression including breast cancer; however, therapeutic approaches targeting KRAS have been widely unsuccessful and KRAS mutant cancers remain unsolved problem in cancer therapy. In this study, we found that a new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one (BHP) can block KRAS-driven breast cancer progression. Importantly, treatment with BHP effectively suppressed the migratory and invasive properties along with epithelial-mesenchymal transition (EMT) in MDA-MB231 breast cancer cells that carry oncogenic KRAS and mesenchymal malignant phenotypes. In parallel, BHP also sensitized the cells to anticancer treatment. Consistently, forced-expression of oncogenic KRAS bestowed the migratory and invasive properties, mesenchymal transition and resistance to anticancer treatment into normal human mammalian breast cells MCF10A and relatively non-malignant MCF7 and SK-BR3 breast cancer cells; however, treatment with BHP blocked those KRAS-induced malignant phenotypes. Notably, BHP interfered the interaction of KRAS with Raf-1 in concentration-dependent manner, thereby blocking the downstream effectors of KRAS signaling that is PI3K/AKT and ERK. Taken together, our findings indicate that the BHP, an α-pyrone derivative, suppresses malignant breast cancer progression by targeting of oncogenic KRAS signaling pathways.

Original languageEnglish
Pages (from-to)49-57
Number of pages9
JournalCancer Letters
Volume337
Issue number1
DOIs
Publication statusPublished - 2013 Aug 28

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A novel 2-pyrone derivative, BHP, impedes oncogenic KRAS-driven malignant progression in breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Kim, R. K., Suh, Y., Lim, E. J., Yoo, K. C., Lee, G. H., Cui, Y. H., Son, A., Hwang, E., Uddin, N., Yi, J. M., Kang, S. G., & Lee, S. J. (2013). A novel 2-pyrone derivative, BHP, impedes oncogenic KRAS-driven malignant progression in breast cancer. Cancer Letters, 337(1), 49-57. https://doi.org/10.1016/j.canlet.2013.05.023